Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of CT-707 + toripalimab + gemcitabine in advanced pancreatic cancer
CTR20222060Phase 2Active
- Sponsor
- Beijing Sailintai Pharmaceutical Technology
- Start
- Oct 2022
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of conteltinib, toripalimab, gemcitabine in pancreatic cancer (PC), sponsored by Beijing Sailintai Pharmaceutical Technology. Started Oct 2022; status: active.
02
Drugs
conteltinibtoripalimabgemcitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on CTR20222060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222060.